Swiss National Bank - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 144 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.

Quarter-by-quarter ownership
Swiss National Bank ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$629,000
-25.3%
165,5000.0%0.00%0.0%
Q4 2019$842,000
+4.7%
165,500
+4.0%
0.00%0.0%
Q3 2019$804,000
-15.5%
159,100
+3.2%
0.00%0.0%
Q2 2019$951,000
+33.0%
154,1000.0%0.00%0.0%
Q1 2019$715,000
+15.5%
154,100
+4.5%
0.00%0.0%
Q4 2018$619,000
-33.0%
147,4000.0%0.00%0.0%
Q3 2018$924,000
-6.1%
147,400
+20.4%
0.00%0.0%
Q2 2018$984,000
+7.8%
122,4000.0%0.00%0.0%
Q1 2018$913,000
+32.7%
122,400
+5.8%
0.00%0.0%
Q4 2017$688,000
-19.2%
115,7000.0%0.00%0.0%
Q3 2017$852,000
+8.4%
115,7000.0%0.00%0.0%
Q2 2017$786,000
-28.0%
115,7000.0%0.00%0.0%
Q1 2017$1,092,000
+9.2%
115,7000.0%0.00%
-50.0%
Q4 2016$1,000,000
+36.6%
115,7000.0%0.00%
+100.0%
Q3 2016$732,000
+50.0%
115,7000.0%0.00%0.0%
Q2 2016$488,000
+0.2%
115,7000.0%0.00%0.0%
Q1 2016$487,000
-15.9%
115,700
+22.4%
0.00%0.0%
Q4 2015$579,000
+7.0%
94,5000.0%0.00%0.0%
Q3 2015$541,000
-12.5%
94,500
+14.1%
0.00%
-50.0%
Q2 2015$618,00082,8000.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q2 2019
NameSharesValueWeighting ↓
Broadfin Capital, LLC 8,951,169$54,871,0003.38%
Virtus ETF Advisers LLC 103,807$636,0001.75%
BKS ADVISORS, LLC 291,150$1,785,0000.92%
Piermont Capital Management Inc. 363,549$2,229,0000.71%
TUDOR INVESTMENT CORP ET AL 2,370,760$14,532,0000.41%
SEARLE & CO. 60,000$349,0000.34%
TURNER INVESTMENTS LLC 252,785$1,550,0000.32%
RICE HALL JAMES & ASSOCIATES, LLC 891,672$5,466,0000.31%
Phocas Financial Corp. 635,333$3,895,0000.30%
TFS CAPITAL LLC 398,283$2,441,0000.26%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders